Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

NCT01879553 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
126
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Vaccines